NexImmune, Inc. (NEXI)

Market Cap	529.98K
Revenue (ttm)	n/a
Net Income (ttm)	-20.62M
Shares Out	1.39M
EPS (ttm)	-17.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	330
Open	0.355
Previous Close	n/a
Day's Range	0.355 - 0.380
52-Week Range	0.330 - 28.700
Beta	1.85
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: NEXI